1 附：董事候选人简历 一、程洪进先生 本事项尚需提交本公司 2024 年年度股东大会审议并采用累积投票方 式表决。 特此公告。 广州白云山医药集团股份有限公司 关于补选董事的公告 广州白云山医药集团股份有限公司董事会 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 29 日 证券代码：600332 证券简称：白云山 公告编号：2025－037 广州白云山医药集团股份有限公司（以下简称"本公司"）于 2025 年 4 月 29 日召开了本公司第九届董事会第二十三次会议，审议通过了《关 于提名程洪进先生为本公司第九届董事会执行董事候选人并建议其 2025 年度薪酬的议案》和《关于提名唐和平先生为本公司第九届董事会执行董 事候选人并建议其 2025 年度薪酬的议案》。根据《公司法》等法律法规 和《公司章程》的规定，经本公司控股股东广州医药集团有限公司（"广 药集团"）推荐，本公司第九届董事会提名与薪酬委员会 2025 年第 2 次 会议对上述董事候选人的个人简历、任职资格等进行了审查，本公司董事 会同意提名程 ...

Financial Performance - The company's operating revenue for the first quarter was RMB 22,473,408,393, a decrease of 2.06% compared to RMB 22,946,211,892 in the same period last year[8]. - Net profit attributable to shareholders was RMB 1,821,313,254, reflecting a decline of 6.99% from RMB 1,958,118,124 year-on-year[8]. - Basic and diluted earnings per share both stood at RMB 1.120, down 6.99% from RMB 1.204 in the same period last year[8]. - Operating profit for Q1 2025 was RMB 2,227,367,213.28, down 9.15% from RMB 2,452,250,842.21 in Q1 2024[29]. - Net profit for Q1 2025 was RMB 1,857,449,310.65, down 8.54% from RMB 2,031,724,927.91 in Q1 2024[29]. - Earnings per share for Q1 2025 was RMB 1.120, compared to RMB 1.204 in Q1 2024, reflecting a decrease of 6.98%[31]. - Other comprehensive income after tax for Q1 2025 was RMB (6,571,384.79), compared to RMB 1,506,821.70 in Q1 2024, indicating a significant decline[29]. Cash Flow - The net cash flow from operating activities was negative at RMB (3,897,258,025), worsening by 24.19% compared to RMB (3,138,186,617) in the previous year[8]. - In Q1 2025, the cash inflow from operating activities was RMB 15.91 billion, a decrease of 5.2% compared to RMB 16.79 billion in Q1 2024[32]. - The net cash outflow from operating activities was RMB (3.90) billion, worsening from RMB (3.14) billion in the same period last year[32]. - Cash inflow from investment activities totaled RMB 727.84 million, significantly higher than RMB 75.78 million in Q1 2024[33]. - The net cash outflow from investment activities was RMB (738.65) million, compared to RMB (282.99) million in Q1 2024[33]. - Cash inflow from financing activities was RMB 4.31 billion, down from RMB 6.27 billion in Q1 2024[33]. - The net cash inflow from financing activities was RMB 1.03 billion, a decrease from RMB 1.94 billion in the previous year[33]. - The net increase in cash and cash equivalents for Q1 2025 was RMB (3.60) billion, compared to RMB (1.48) billion in Q1 2024[34]. - The ending balance of cash and cash equivalents was RMB 12.70 billion, down from RMB 18.34 billion at the end of Q1 2024[34]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 80,047,799,450, a decrease of 2.00% from RMB 81,683,611,521 at the end of the previous year[8]. - Total current assets amounted to RMB 55.67 billion, a decrease of 3.6% from RMB 57.76 billion as of December 31, 2024[24]. - Total non-current assets reached RMB 24.37 billion, an increase of 1.9% from RMB 23.92 billion[25]. - Total liabilities decreased to RMB 40.41 billion, down 8.6% from RMB 43.91 billion[26]. - Short-term borrowings slightly decreased to RMB 9.01 billion from RMB 9.12 billion[26]. - The company reported a total asset value of RMB 80.05 billion, a decrease from RMB 81.68 billion[25]. - The total liabilities and equity as of March 31, 2025, were RMB 80,047,799,450.33, compared to RMB 81,683,611,520.64 at the end of 2024, showing a decrease of 2.01%[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 93,536[18]. - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., held 45.04% of the shares, totaling 732,305,103 shares[19]. - Shareholders' equity attributable to the parent company increased by 5.05% to RMB 37,719,037,765 from RMB 35,904,527,869 at the end of the previous year[8]. - The total equity attributable to shareholders increased to RMB 37,719,037,764.76 as of March 31, 2025, up from RMB 35,904,527,868.59 at the end of 2024, representing a growth of 5.03%[27]. - Minority interest increased to RMB 1,919,881,939.30 as of March 31, 2025, from RMB 1,865,107,877.80 at the end of 2024, reflecting a growth of 2.91%[27]. Operational Insights - The company reported a non-operating income of RMB 41,380,031 from government subsidies during the period[13]. - The company has not reported any changes in major shareholders or their participation in financing activities[22]. - There are no significant reminders or additional important information regarding the company's operational status during the reporting period[23]. - Research and development expenses for Q1 2025 were RMB 143,713,072.16, a decrease of 22.73% compared to RMB 186,139,000.55 in Q1 2024[28]. - Accounts receivable increased to RMB 17.65 billion, up 11.7% from RMB 15.73 billion in the previous period[24]. - Inventory decreased to RMB 10.82 billion, down 15.5% from RMB 12.81 billion as of December 31, 2024[24]. - The impact of exchange rate changes on cash and cash equivalents was an increase of RMB 6.33 million, compared to RMB 2.43 million in Q1 2024[34].

Group 1 - The core viewpoint of the news indicates that the Artemisinin concept sector experienced a decline of 0.81%, ranking among the top declines in the concept sector [1] - Within the Artemisinin concept sector, major companies such as Kunming Pharmaceutical Group, New Harmony, and Rundu Co., Ltd. saw significant declines, while companies like Baihua Pharmaceutical, China Resources Sanjiu, and Zhejiang Medicine recorded gains of 1.21%, 0.75%, and 0.75% respectively [1] Group 2 - The financial data shows that the Artemisinin concept sector had a net outflow of 96 million yuan, with eight stocks experiencing net outflows, led by Kunming Pharmaceutical Group with a net outflow of 62.05 million yuan [2] - Other companies with notable net outflows include Rundu Co., Ltd. with 11.84 million yuan, Fosun Pharmaceutical with 9.02 million yuan, and Zhejiang Medicine with 6.48 million yuan [2] - Conversely, the stocks with the highest net inflows included Baihua Pharmaceutical and New Harmony, with net inflows of 6.07 million yuan and 1.19 million yuan respectively [2]

广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 子公司广州白云山明兴制药有限公司（以下简称"明兴药业"）收 到广东省药品监督管理局核准签发的《药品生产许可证》，同意明 兴药业核减生产范围、生产车间和生产线。现将相关情况公告如下： 一、《药品生产许可证》基本情况 企业名称：广州白云山明兴制药有限公司 证券代码：600332 证券简称：白云山 公告编号：2025－033 许可证编号：粤 20160012 分类码：AhzxBzCzDhz 注册地址：广州市海珠区工业大道北 48 号 发证机关：广东省药品监督管理局 有效期至：2025 年 11 月 22 日 生产地址和生产范围： 1、广州市黄埔区尖塔山路 1 号，原料药［门冬酰胺酶（欧文）］； 2、广州市海珠区工业大道北 48 号，片剂，硬胶囊剂，颗粒剂，合剂， 乳剂，小容量注射剂（含激素类），中药前处理及提取车间（口服制 剂、注射制剂）；3、广州市从化明 ...

廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）茲通 告謹定於 2025 年 4 月 29 日（星期二）舉行董事會會議，藉以審議及批准 本公司及其附屬公司截至 2025 年 3 月 31 日止三個月未經審計財務業績及 處理其他事項（如有）。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025 年 4 月 15 日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會會議召開日期 於本公告日，本公司董事會成員包括執行董事李小軍先生、楊軍先生、程寧女士與黎洪先生，及獨 立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 1 ...

Core Insights - The overall performance of traditional Chinese medicine (TCM) companies shows a divergent trend amid intensified market competition, fluctuating raw material prices, and changing policy environments [1] - Companies are actively seeking new growth avenues for long-term development [1] Revenue Performance - Baiyunshan leads with a revenue of 749.93 billion, but experienced a slight decline of 0.69% year-on-year [3] - Yunnan Baiyao follows with a revenue of 400.33 billion, maintaining steady growth supported by diversified products [3] - Taiji Group and Kangyuan Pharmaceutical saw significant revenue declines, with Taiji's revenue dropping by 20.72% to 123.86 billion [3][4] - Taiji's flagship product, Huoxiang Zhengqi Oral Liquid, faced a 35.34% drop in sales, indicating market share erosion [3][4] Profitability Analysis - Yunnan Baiyao reported a leading net profit of 47.49 billion, up 16.02%, while Huaren Sanjiu's net profit grew by 18.05% to 33.68 billion [6] - Six out of fifteen companies experienced a decline in net profit, indicating severe profitability challenges [6] - Taiji Group's net profit plummeted by 96.76% to 0.27 billion, attributed to tax payment issues [6][7] Cost Pressures - Rising raw material prices significantly impacted profit margins, with notable increases in costs for key ingredients [8][9] - For instance, the price of natural cow bile used in Tongrentang's products surged from 650,000 to 1,650,000 per kilogram, leading to a decrease in gross margin [8] R&D and Innovation Challenges - Many TCM companies face low R&D investment and high sales expenses, limiting their growth potential [9][10] - Approximately 40% of the surveyed companies had R&D expenses below 200 million, with seven companies reporting a year-on-year decline in R&D spending [9] - Companies are increasingly relying on traditional products, hindering innovation and the introduction of competitive new products [9] Strategic Shifts - Companies are exploring new growth strategies, such as East A Ejiao's focus on men's health products and Jichuan Pharmaceutical's partnerships for business development [10][11] - Some companies are integrating AI and digital technologies into their operations to modernize and enhance product offerings [11]

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 2,835,496,163.51 for the fiscal year 2024, with a base net profit of RMB 1,114,566,368.85[4] - The company reported an undistributed profit of RMB 7,524,341,276.23 after accounting for the statutory surplus reserve and cash dividends paid[4] - The company's operating revenue for 2024 was RMB 74,992,820 thousand, a decrease of 0.69% compared to RMB 75,515,404 thousand in 2023[27] - Net profit attributable to shareholders for 2024 was RMB 2,835,496 thousand, down 30.09% from RMB 4,055,679 thousand in 2023[27] - The net cash flow from operating activities decreased by 16.11% to RMB 3,442,427 thousand in 2024 from RMB 4,103,625 thousand in 2023[27] - Total profit amounted to RMB 3,607,580 thousand, reflecting a year-on-year decline of 29.41%[39] - The company's total liabilities increased by 4.78% to RMB 43,913,976 thousand at the end of 2024, compared to RMB 41,909,054 thousand at the end of 2023[27] - The asset-liability ratio increased to 53.76% in 2024 from 53.33% in 2023, an increase of 0.43 percentage points[28] - The company's total equity attributable to shareholders at year-end was RMB 35,904,528 thousand, an increase from the previous year[35] Dividend and Profit Distribution - A cash dividend of RMB 0.40 per share (before tax) is proposed, totaling RMB 650,316,379.60 based on a total share capital of 1,625,790,949 shares as of December 31, 2024[4] - The company plans to submit the profit distribution proposal to the shareholders' meeting for approval[5] Risks and Challenges - There are no significant risks that could materially affect the company's operations during the reporting period[6] - The report outlines various risks and challenges the company may face in its future development[6] - The company emphasizes that forward-looking statements in the report do not constitute a commitment to investors, urging them to be aware of investment risks[9] Research and Development - Investment in R&D for new products increased by 25%, focusing on innovative drug formulations and biopharmaceuticals[24] - The group has over 200 ongoing research projects, including traditional Chinese medicine, generic drugs, biosimilars, and medical devices, reflecting a strong commitment to innovation[42] - The company has five national-level R&D institutions and 15 provincial-level technology centers, indicating a strong commitment to innovation[92] - The total R&D expenditure amounted to RMB 828,407 thousand, representing 4.26% of operating revenue[123] - The company is actively pursuing innovation in drug development, focusing on both introducing projects and independent research and development[182] Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 12% for the next fiscal year, driven by new product launches and market expansion strategies[24] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by 2025[24] - The company plans to continue its international expansion and enhance e-commerce channels to drive sales growth[40] - The company is actively involved in expanding its market presence through the introduction of new formulations and product types[162] - The company aims to leverage its new product approvals to strengthen its market position and drive future growth[191] Product Development and Portfolio - The company has a strong pipeline of products aimed at addressing respiratory and gastrointestinal conditions, among others[162] - The company is enhancing its product pipeline with new approvals for drugs targeting various infections and conditions, including antibiotics and cardiovascular treatments[197] - The company is expanding its product line with traditional Chinese medicine, such as Sangju Granules, aimed at alleviating symptoms of wind-heat colds[200] - The company has ongoing research and development efforts for new products, including the Qingkailing series and Acetaminophen series, aimed at treating various conditions[162] Financial Health and Investment - The total assets of the company increased by 10% to RMB 15 billion, indicating strong financial health and investment capacity[24] - The company’s debt-to-equity ratio improved to 0.5, showcasing a stronger balance sheet and reduced financial risk[24] - The group plans to invest approximately RMB 2.014 billion in capital expenditures in 2025, up from RMB 1.55 billion in 2024, focusing on R&D and production facilities[135] Regulatory Compliance and Quality Management - The financial report has been audited by Da Xin Accounting Firm, which issued a standard unqualified opinion[8] - The financial report is prepared in accordance with Chinese accounting standards and is available in both Chinese and English[7] - The group adheres to national GMP standards in production, ensuring quality control throughout the manufacturing process from raw material procurement to final product delivery[81] - The company plans to strengthen its quality management system in line with the new TCM standard management regulations, focusing on quality control methods and improving the TCM quality standard system[52] Sales and Distribution - The pharmaceutical retail network consists of 157 outlets, primarily located in Guangdong and Hainan, including 60 "Jianmin" chain stores and 65 Guangzhou Pharmaceutical chain stores[87] - The group has developed an e-commerce sales system, leveraging platforms like Tmall and JD.com to expand product sales reach and adapt to new economic models[80] - The group actively integrates internal sales resources, forming a pharmaceutical sales platform centered around Baiyunshan Pharmaceutical Sales Company, enhancing sales efficiency[80] Industry Trends and Competitive Landscape - In 2024, the pharmaceutical distribution sector is expected to see increased concentration and intensified competition, with a focus on enhancing service capabilities and expanding distribution networks[42] - The pharmaceutical industry is characterized as non-cyclical, with certain products experiencing seasonal demand spikes, particularly in the case of flu medications and herbal teas[67] - The group is recognized as one of the largest pharmaceutical enterprises in China, with a comprehensive layout in the biopharmaceutical health industry and a strong market position[48]

证券代码：600332 证券简称：白云山 公告编号：2025－032 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 全资子公司广州白云山明兴制药有限公司（以下简称"明兴药业"） 收到广东省药品监督管理局核准签发的《药品生产许可证》，同意 明兴药业新增生产范围和生产线，并通过药品生产质量管理规范符 合性检查。现将相关情况公告如下： 一、《药品生产许可证》基本情况 企业名称：广州白云山明兴制药有限公司 许可证编号：粤 20160012 分类码：AhzxBzCzDhz 注册地址：广州市海珠区工业大道北 48 号 发证机关：广东省药品监督管理局 有效期至：2025 年 11 月 22 日 生产地址和生产范围： 1、广州市黄埔区尖塔山路 1 号，冻干粉针剂（含抗肿瘤药）， 原料药［门冬酰胺酶（欧文）］；2、广州市海珠区工业大道北 48 号 ，片剂，硬胶囊剂，颗粒剂，合剂，乳剂，小容量注射剂（含激素类）， ...

Industry Overview - Chinese herbal medicine is a unique drug used in traditional Chinese medicine for disease prevention and treatment, encompassing both herbal medicine and traditional Chinese drugs [1][5] - The market size of Chinese herbal medicine planting in China is projected to grow from 156.3 billion yuan in 2019 to 295.68 billion yuan in 2024, with a year-on-year growth rate of 30.2% [9] - The planting area for Chinese herbal medicine has increased from 52.5 million mu in 2019 to 59.56 million mu in 2024, reflecting a year-on-year growth rate of 5.87% [5][9] Industry Chain - The upstream of the industry chain includes the planting of Chinese herbal medicine, breeding of medicinal animals, and collection of raw materials, with key players such as Baiyunshan, Kangmei Pharmaceutical, and Yunnan Baiyao [2] - The midstream involves the processing and manufacturing of Chinese herbal products, including traditional Chinese medicine and herbal pieces, with companies like Kangmei Pharmaceutical and Huaren Sanjiu leading this segment [2] - The downstream focuses on the distribution and sales of Chinese herbal products through traditional pharmacies and e-commerce platforms [2] Market Dynamics - The demand for Chinese herbal medicine is increasing due to factors such as industrialization, urbanization, and an aging population, alongside supportive government policies [9] - The recognition of traditional Chinese medicine in international markets is also on the rise, contributing to the industry's rapid growth [9] Competitive Landscape - The competitive landscape of the Chinese herbal medicine planting industry is tiered based on registered capital, with the first tier exceeding 1 billion yuan, including companies like Yunnan Baiyao and Kunming Pharmaceutical [11][13] - The second tier has registered capital between 500 million to 1 billion yuan, featuring companies like Yibai Pharmaceutical and Dong'e Ejiao [11][13] - The third tier consists of companies with registered capital below 500 million yuan, such as Foci Pharmaceutical and Zhendong Pharmaceutical [11][13] Development Trends - The establishment of geographical indication and ecological planting models is accelerating the construction of authentic medicinal material protection zones [17] - The standardization of seeds and seedlings is expected to overcome industry bottlenecks, with significant improvements in the coverage of quality seeds [17] - International certifications such as EU organic certification and US NOP standards are becoming essential for export enterprises, enhancing the competitiveness of Chinese herbal products in global markets [18]

FF301 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,405,890,949 | RMB | | 1 RMB | | 1,405,890,949 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 1,405,890,949 | RMB | | 1 RMB | | 1,405,890,949 | 本月底法定/註冊股本總額： RMB 1,625,790,949 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團 ...